FITC-Labeled Alendronate as an In Vivo Bone pH Sensor.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
01
2020
revised:
05
03
2020
accepted:
06
04
2020
entrez:
19
6
2020
pubmed:
19
6
2020
medline:
23
3
2021
Statut:
epublish
Résumé
pH is a critical indicator of bone physiological function and disease status; however, noninvasive and real-time sensing of bone pH in vivo has been a challenge. Here, we synthesized a bone pH sensor by labeling alendronate with the H+-sensitive dye fluorescein isothiocyanate (Aln-FITC). Aln-FITC showed selective affinity for hydroxyapatite (HAp) rather than other calcium materials. An in vivo biodistribution study showed that Aln-FITC can be rapidly and specifically delivered to rat bones after caudal vein injection, and the fluorescence lasted for at least 12 h. The fluorescence intensity of Aln-FITC binding to HAp linearly decreased when the pH changed from 6 to 12. This finding was further confirmed on bone blocks and perfused bone when the pH changed from 6.8 to 7.4, indicating unique pH-responsive characteristics in the bone microenvironment. Aln-FITC was then preliminarily applied to evaluate the changes in bone pH in a nude mouse acidosis model. Our results demonstrated that Aln-FITC might have the potential for minimally invasive and real-time in vivo bone pH sensing in preclinical studies of bone healing, metabolism, and cancer mechanisms.
Identifiants
pubmed: 32550231
doi: 10.1155/2020/4012194
pmc: PMC7256770
doi:
Substances chimiques
Durapatite
91D9GV0Z28
Fluorescein-5-isothiocyanate
I223NX31W9
Alendronate
X1J18R4W8P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4012194Informations de copyright
Copyright © 2020 Yuzhou Li et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.
Références
Sci Rep. 2017 Dec 13;7(1):17484
pubmed: 29235482
Tissue Eng Part C Methods. 2012 Oct;18(10):740-6
pubmed: 22462800
Biochem Biophys Rep. 2017 Feb 27;10:17-25
pubmed: 28955732
ACS Nano. 2016 Jun 28;10(6):5759-68
pubmed: 27176123
Talanta. 2012 Sep 15;99:194-201
pubmed: 22967541
J Biomed Mater Res. 1994 Dec;28(12):1439-43
pubmed: 7876283
J Biomed Mater Res. 2002 May;60(2):292-9
pubmed: 11857436
Drug Deliv. 2018 Nov;25(1):187-197
pubmed: 29303005
Nat Methods. 2016 Jul;13(7):557-62
pubmed: 27240257
ACS Sens. 2018 Nov 26;3(11):2278-2285
pubmed: 30350591
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):990-5
pubmed: 24395775
Biosens Bioelectron. 2016 Jun 15;80:79-83
pubmed: 26807518
Clin Chim Acta. 2016 Apr 1;455:181-8
pubmed: 26877058
ACS Appl Mater Interfaces. 2018 Jul 18;10(28):23700-23710
pubmed: 29939711
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2432-7
pubmed: 21262842
Pharm Res. 2005 Jul;22(7):1079-87
pubmed: 16028008
Expert Opin Drug Deliv. 2015;12(9):1443-58
pubmed: 25739860
Analyst. 2019 Apr 23;144(9):2984-2993
pubmed: 30888348
Int J Mol Sci. 2019 Mar 04;20(5):
pubmed: 30836626
Chem Commun (Camb). 2018 Jan 2;54(3):299-302
pubmed: 29239411
J Cell Sci. 2011 Jan 15;124(Pt 2):157-60
pubmed: 21187342
Mol Pharmacol. 2006 May;69(5):1624-32
pubmed: 16501031
Org Biomol Chem. 2017 Sep 26;15(37):7936-7943
pubmed: 28901370
Acta Neurochir (Wien). 2018 Feb;160(2):317-324
pubmed: 29275519
Biotechniques. 2005 Dec;39(6 Suppl):S33-7
pubmed: 20158502
Cancer Res. 1994 Nov 1;54(21):5670-4
pubmed: 7923215
Oncol Rep. 2016 Oct;36(4):2025-32
pubmed: 27498716
Talanta. 2020 Mar 1;209:120436
pubmed: 31892062
Anal Chem. 2015 Jun 16;87(12):5897-904
pubmed: 25893705
Drug Deliv Transl Res. 2016 Apr;6(2):105-20
pubmed: 26625850
J Nutr. 2008 Feb;138(2):415S-418S
pubmed: 18203913